SynthesisPloS one2015
A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Pooled it
- Pooled it
- Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.The Cochrane database of systematic reviews · 2018Pooled it
- New insights in diagnosis and treatment for Retinopathy of Prematurity.International ophthalmology · 2016Pooled it
- Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study.Acta ophthalmologica · 2022Trial
- Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.JAMA pediatrics · 2018Trial
- Comment on "Ocular surface inflammatory cytokines as a biomarker for retinopathy of prematurity".Eye (London, England) · 2026Article
- Reactivation of retinopathy of prematurity after intravitreal bevacizumab: incidence, risk factors, and retreatment requirements.BMC ophthalmology · 2026Article
- Review
- Retinopathy of Prematurity and MicroRNAs.Biomedicines · 2025Review
- A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity.Journal of clinical medicine · 2025Review
- Real-World Visual and Anatomical Outcomes of Laser Therapy versus Intravitreal Anti-Vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A 10-Year Retrospective Cohort Study at a Tertiary Center in Thailand.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Natural Products in the Treatment of Retinopathy of Prematurity: Exploring Therapeutic Potentials.International journal of molecular sciences · 2024Review
- Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection.BMC ophthalmology · 2024Article
- Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis.Biomolecules & biomedicine · 2023Article
- Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies.International journal of general medicine · 2023Review
- Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.JAMA ophthalmology · 2022Article
- The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.Eye (London, England) · 2022Review
- Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence.International ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLaser photocoagulation is the current gold standard treatment for proliferative retinopathy of prematurity (ROP). However, it permanently reduces the visual field and might induce myopia. Vascular endothelial growth factor (VEGF) inhibitors for the treatment of ROP may enable continuing vascularization of the retina, potentially allowing the preservation of the visual field. However, for their use in infants concern remains. This meta-analysis explores the safety of VEGF inhibitors.
methodsThe Ovid Interface was used to perform a systematic review of the literature in the databases PubMed, EMBASE and the Cochrane Library.
resultsThis meta-analysis included 24 original reports (including 1.457 eyes) on VEGF inhibitor treatment for ROP. The trials were solely observational except for one randomized and two case-control studies. We estimated a 6-month risk of retreatment per eye of 2.8%, and a 6-month risk of ocular complication without the need of retreatment of 1.6% per eye. Systemic complications were only reported as isolated incidents. DISCUSSION: VEGF inhibitors seem to be associated with low recurrence rates and ocular complication rates. They may have the benefit of potentially allowing the preservation of visual field and lower rates of myopia. Due to the lack of data, the risk of systemic side effects cannot be assessed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.